跳至主要内容
临床试验/NCT05499663
NCT05499663
已完成
1 期

Leveraging Technology to Address POST-Treatment Health Outcomes of Cancer Survivors (POSTHOC-II): A Phase II Survivorship Care Plan Randomized Controlled Trial

University of Maryland, Baltimore1 个研究点 分布在 1 个国家目标入组 51 人2024年3月5日

概览

阶段
1 期
干预措施
POSTHOC app
疾病 / 适应症
Survivorship
发起方
University of Maryland, Baltimore
入组人数
51
试验地点
1
主要终点
Number of Participants Who Logged Data at Least Three Times in the POSTHOC App
状态
已完成
最后更新
2个月前

概览

简要总结

At the end of cancer treatment, many patients are still dealing with symptoms of cancer and side effects of treatment. Many are also left in a surreal mental state with uncertainty regarding the future of their health. Survivorship Care Plans are plans that are provided to individuals at the completion of cancer treatment (i.e., chemotherapy, surgery, radiation). Survivorship Care Plans describe the details of a person's diagnosis and treatment, as well as provide recommendations for follow-up appointments, referrals, and healthy behaviors to accelerate recovery and prevent recurrence (e.g., diet, exercise, smoking cessation). Survivorship Care Plans are currently static documents that are provided via paper and become outdated as soon as the person's health status changes. Therefore, there is a need to digitize Survivorship Care Plans to improve the accessibility, modifiability, and longevity of the plan. In addition, with current technology, there is an opportunity for Survivorship Care Plans to be linked with mobile devices and activity trackers so that people can track health behaviors and compare them to their clinical goals, enabling people to take charge of their own health. Charles River Analytics developed an app called POSTHOC (POST-treatment Healthcare Outcomes for Cancer survivors) that digitizes the Survivorship Care Plan with goals to integrate it into the digital medical record.

Herein, phase I/II feasibility/preliminary efficacy randomized controlled trial is being conducted among 54 patients with cancer who recently completed adjuvant treatment for cancer (e.g., chemotherapy, radiotherapy, surgery) to compare 12 weeks of the POSTHOC app as part of the Survivorship Care Plan vs. the usual care Survivorship Care Plan on total symptom burden. Participants will be randomized 2:1, POSTHOC:usual care. All participants will be asked to download the POSTHOC app to assess technical compatibility and for data collection purposes (i.e., step count via Fitbit, ecological momentary assessment). All participants will have a "lite" version of the app for baseline. Upon randomization, those randomized to the POSTHOC group will be provided with their Survivorship Care Plan via the app, and will choose to focus on nutrition or exercise for the duration of the study, based on their individual plan and personal preferences. These features will also become accessible in the app. At baseline, 6 weeks, and 12 weeks, patient-reported outcomes will be evaluated including total symptom burden, diet, and physical activity. Extensive quantitative and qualitative feedback will also be collected on the usability of the app from those in the POSTHOC arm in order to improve the app for future implementation studies.

注册库
clinicaltrials.gov
开始日期
2024年3月5日
结束日期
2025年3月20日
最后更新
2个月前
研究类型
Interventional
研究设计
Parallel
性别
All

研究者

责任方
Principal Investigator
主要研究者

Amber Kleckner

Assistant Professor

University of Maryland, Baltimore

入排标准

入选标准

  • Have had a cancer diagnosis (any type)
  • Will soon or have recently completed treatment (within the past 12 weeks) with chemotherapy, radiotherapy, or surgery with curative intent
  • Must have received, plans to receive, or open to receiving a Survivorship Care Plan (SCP) as per their provider
  • Have access to a device capable of running the POSTHOC app and Fitbit app (e.g., Android or Apple smartphone) and reliable Internet access
  • Be at least 18 years of age
  • Be able to read and understand English, and
  • Be able to provide written informed consent

排除标准

  • Have planned surgery, radiotherapy, or surgery during the study period (hormonal and biologic therapy is allowed)

研究组 & 干预措施

POSTHOC app

干预措施: POSTHOC app

Control

结局指标

主要结局

Number of Participants Who Logged Data at Least Three Times in the POSTHOC App

时间窗: 12 weeks

Number of participants who logged data at least three times in the POSTHOC app

Usefulness of POSTHOC App

时间窗: 6 weeks

7-point Likert scale for usefulness flanked by 1=not at all useful and 7=extremely useful

Usefulness of POSTHOC App

时间窗: 12 weeks

7-point Likert scale for usefulness flanked by 1=not at all useful and 7=extremely useful

Likely to Recommend the POSTHOC App

时间窗: 6 weeks

7-point Likert scale flanked by 1=not at all likely to recommend to others and 7=extremely likely

Likely to Recommend the POSTHOC App

时间窗: 12 weeks

7-point Likert scale flanked by 1=not at all likely to recommend to others and 7=extremely likely

次要结局

  • Cumulative Symptom Burden(12 weeks)
  • Cumulative Symptom Burden(6 weeks)

研究点 (1)

Loading locations...

相似试验